All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mNSCLC - L2 - PDL1 positive, anti-PD-(L)1 vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
0.63 [0.42 ; 0.94 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 126 NA not evaluable progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
0.71 [0.49 ; 1.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 126 NA not evaluable objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
3.87 [1.55 ; 9.69 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 126 NA not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
0.24 [0.01 ; 5.43 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
0.36 [0.18 ; 0.75 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
3.27 [0.63 ; 16.86 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
0.63 [0.24 ; 1.67 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
1.73 [0.81 ; 3.73 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
1.02 [0.33 ; 3.10 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
0.19 [0.08 ; 0.46 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
0.13 [0.05 ; 0.36 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
1.02 [0.24 ; 4.26 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
0.25 [0.01 ; 5.61 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
0.08 [0.00 ; 1.41 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
0.16 [0.01 ; 3.32 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
0.25 [0.01 ; 5.61 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
0.09 [0.01 ; 1.76 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
1.02 [0.06 ; 16.62 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
1.02 [0.02 ; 52.03 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
1.02 [0.06 ; 16.62 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
2.05 [0.07 ; 62.21 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 01:09 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 177
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563